Profile of etodolac: Pharmacokinetic evaluation in special populations View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-03

AUTHORS

D. C. Brater, K. C. Lasseter

ABSTRACT

The pharmacokinetics of etodolac, a new nonsteroidal anti-inflammatory drug, were compared in normal subjects, in patients with renal and hepatic disease, and in elderly patients. In 28 normal subjects, orally administered etodolac was rapidly absorbed. By 1.2 hours after ingestion of a 200 mg dose, the maximum serum concentration (Cmax) averaged 15.9 micrograms/ml, with more than 99% of the drug bound to serum protein. Clearance was primarily hepatic. The mean half-life (t1/2) was 6 to 7 hours. There were no apparent differences in Cmax, the time at which Cmax occurred (tmax), area under the serum concentration/time curve (AUC0-24), or t1/2 between groups of young men (n = 20), elderly men (n = 24), and elderly men with osteoarthritis (n = 20), after a single dose of etodolac or after 7 days of subchronic administration. Moreover there was no evidence of accumulation. There also were no differences in Cmax, tmax, AUC0-24 or t1/2 between groups of normal subjects (n = 10) and patients with mild-to-moderate renal impairment (n = 10). Patients with end-stage renal disease who were receiving chronic hemodialysis had the same mean serum concentration of free drug as normal subjects, even though mean serum levels of protein-bound etodolac were slightly lower than those in the normal subjects. The only significant (p less than 0.05) difference between patients with stable hepatic cirrhosis and normal, age-matched subjects was a slightly shorter tmax in the cirrhotic subjects (1.1 vs. 1.4 hours). These findings suggest that no alteration of etodolac dosage would be necessary in these high-risk groups. More... »

PAGES

25-35

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02214107

DOI

http://dx.doi.org/10.1007/bf02214107

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036724020

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2525981


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents, Non-Steroidal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etodolac", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Half-Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoleacetic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Failure, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoarthritis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wishard Memorial Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417143.4", 
          "name": [
            "Department of Medicine, Division of Clinical Pharmacology, Wishard Memorial Hospital - WOP320, 1001 W. Tenth St., 46202, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brater", 
        "givenName": "D. C.", 
        "id": "sg:person.01161574734.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161574734.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Clinical Pharmacology Associates, Miami, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lasseter", 
        "givenName": "K. C.", 
        "id": "sg:person.010430736134.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010430736134.54"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/clpt.1986.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006338285", 
          "https://doi.org/10.1038/clpt.1986.94"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/03602538108994036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006889200"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197510022931406", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014354142"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.284.6326.1372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017933691"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bdd.2510050109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021043713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498258609043518", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022169678"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198403013100905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024666290"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1985.244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024842472", 
          "https://doi.org/10.1038/clpt.1985.244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198205063061804", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025273847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ki.1980.179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033782308", 
          "https://doi.org/10.1038/ki.1980.179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.285.6334.62", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034388776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(82)91953-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035303847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198503283121305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042677914"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.2600720316", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046369571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0049-0172(86)80005-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050370504"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-03", 
    "datePublishedReg": "1989-03-01", 
    "description": "The pharmacokinetics of etodolac, a new nonsteroidal anti-inflammatory drug, were compared in normal subjects, in patients with renal and hepatic disease, and in elderly patients. In 28 normal subjects, orally administered etodolac was rapidly absorbed. By 1.2 hours after ingestion of a 200 mg dose, the maximum serum concentration (Cmax) averaged 15.9 micrograms/ml, with more than 99% of the drug bound to serum protein. Clearance was primarily hepatic. The mean half-life (t1/2) was 6 to 7 hours. There were no apparent differences in Cmax, the time at which Cmax occurred (tmax), area under the serum concentration/time curve (AUC0-24), or t1/2 between groups of young men (n = 20), elderly men (n = 24), and elderly men with osteoarthritis (n = 20), after a single dose of etodolac or after 7 days of subchronic administration. Moreover there was no evidence of accumulation. There also were no differences in Cmax, tmax, AUC0-24 or t1/2 between groups of normal subjects (n = 10) and patients with mild-to-moderate renal impairment (n = 10). Patients with end-stage renal disease who were receiving chronic hemodialysis had the same mean serum concentration of free drug as normal subjects, even though mean serum levels of protein-bound etodolac were slightly lower than those in the normal subjects. The only significant (p less than 0.05) difference between patients with stable hepatic cirrhosis and normal, age-matched subjects was a slightly shorter tmax in the cirrhotic subjects (1.1 vs. 1.4 hours). These findings suggest that no alteration of etodolac dosage would be necessary in these high-risk groups.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf02214107", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093299", 
        "issn": [
          "0770-3198", 
          "1434-9949"
        ], 
        "name": "Clinical Rheumatology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Profile of etodolac: Pharmacokinetic evaluation in special populations", 
    "pagination": "25-35", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "aef07ad8571ef4669df2739d89a2714cb48fc5b8e49c2f55940c59c555d63ec3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2525981"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8211469"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02214107"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036724020"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02214107", 
      "https://app.dimensions.ai/details/publication/pub.1036724020"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000361_0000000361/records_53977_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF02214107"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02214107'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02214107'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02214107'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02214107'


 

This table displays all metadata directly associated to this object as RDF triples.

174 TRIPLES      21 PREDICATES      56 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02214107 schema:about N3a24d767cbfe4cf49936670ef10d8854
2 N3ccbc5884c0146819ee04798820e2950
3 N45ec824d9312405a9dda7cc74fe52782
4 N567b5b4720e742f7b5520b26ed24ccd7
5 N65029c8deba84ae98ef11eb258910904
6 N6915b727761949f184293de9bfa7a23e
7 N771d8f9bb5e4426b85117f6bec995d3b
8 N82c1d00916ab4aa7a817cbad35eccc6d
9 N8d9b1bda09b74b2a90472db0ad840ddc
10 Naf02c88c29df42efa2ed09fa34662bf9
11 Ned9232bc640c4284b0606f7fe0b99e83
12 Nfa320f899c5c443f937547f2fe255618
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N902de8bd8a0645929f596b7b6b4f104b
16 schema:citation sg:pub.10.1038/clpt.1985.244
17 sg:pub.10.1038/clpt.1986.94
18 sg:pub.10.1038/ki.1980.179
19 https://doi.org/10.1002/bdd.2510050109
20 https://doi.org/10.1002/jps.2600720316
21 https://doi.org/10.1016/s0049-0172(86)80005-1
22 https://doi.org/10.1016/s0140-6736(82)91953-5
23 https://doi.org/10.1056/nejm197510022931406
24 https://doi.org/10.1056/nejm198205063061804
25 https://doi.org/10.1056/nejm198403013100905
26 https://doi.org/10.1056/nejm198503283121305
27 https://doi.org/10.1136/bmj.284.6326.1372
28 https://doi.org/10.1136/bmj.285.6334.62
29 https://doi.org/10.3109/00498258609043518
30 https://doi.org/10.3109/03602538108994036
31 schema:datePublished 1989-03
32 schema:datePublishedReg 1989-03-01
33 schema:description The pharmacokinetics of etodolac, a new nonsteroidal anti-inflammatory drug, were compared in normal subjects, in patients with renal and hepatic disease, and in elderly patients. In 28 normal subjects, orally administered etodolac was rapidly absorbed. By 1.2 hours after ingestion of a 200 mg dose, the maximum serum concentration (Cmax) averaged 15.9 micrograms/ml, with more than 99% of the drug bound to serum protein. Clearance was primarily hepatic. The mean half-life (t1/2) was 6 to 7 hours. There were no apparent differences in Cmax, the time at which Cmax occurred (tmax), area under the serum concentration/time curve (AUC0-24), or t1/2 between groups of young men (n = 20), elderly men (n = 24), and elderly men with osteoarthritis (n = 20), after a single dose of etodolac or after 7 days of subchronic administration. Moreover there was no evidence of accumulation. There also were no differences in Cmax, tmax, AUC0-24 or t1/2 between groups of normal subjects (n = 10) and patients with mild-to-moderate renal impairment (n = 10). Patients with end-stage renal disease who were receiving chronic hemodialysis had the same mean serum concentration of free drug as normal subjects, even though mean serum levels of protein-bound etodolac were slightly lower than those in the normal subjects. The only significant (p less than 0.05) difference between patients with stable hepatic cirrhosis and normal, age-matched subjects was a slightly shorter tmax in the cirrhotic subjects (1.1 vs. 1.4 hours). These findings suggest that no alteration of etodolac dosage would be necessary in these high-risk groups.
34 schema:genre research_article
35 schema:inLanguage en
36 schema:isAccessibleForFree false
37 schema:isPartOf N088c0b0a393540e29fb488bff64bc844
38 Nd26a4f201d2b4fd7ab04a16c1a711bb1
39 sg:journal.1093299
40 schema:name Profile of etodolac: Pharmacokinetic evaluation in special populations
41 schema:pagination 25-35
42 schema:productId N2544cbfc6ff84e64a113dc71f447d59b
43 N353c5796d8a34617a1799bcdac604e18
44 Nb5646ec17013462695464c00daec659f
45 Nc67bff9444ef4bef98afabab843d173c
46 Ne812d7c120304c2697b59db43c658205
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036724020
48 https://doi.org/10.1007/bf02214107
49 schema:sdDatePublished 2019-04-11T12:10
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher Nc8849d82792d4e5dae410f484e107ed5
52 schema:url http://link.springer.com/10.1007%2FBF02214107
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N088c0b0a393540e29fb488bff64bc844 schema:volumeNumber 8
57 rdf:type schema:PublicationVolume
58 N2544cbfc6ff84e64a113dc71f447d59b schema:name readcube_id
59 schema:value aef07ad8571ef4669df2739d89a2714cb48fc5b8e49c2f55940c59c555d63ec3
60 rdf:type schema:PropertyValue
61 N353c5796d8a34617a1799bcdac604e18 schema:name nlm_unique_id
62 schema:value 8211469
63 rdf:type schema:PropertyValue
64 N3a24d767cbfe4cf49936670ef10d8854 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Humans
66 rdf:type schema:DefinedTerm
67 N3ccbc5884c0146819ee04798820e2950 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Male
69 rdf:type schema:DefinedTerm
70 N45ec824d9312405a9dda7cc74fe52782 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Adult
72 rdf:type schema:DefinedTerm
73 N567b5b4720e742f7b5520b26ed24ccd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Half-Life
75 rdf:type schema:DefinedTerm
76 N5d0d924949fb4e6cb04b91f168f08b52 rdf:first sg:person.010430736134.54
77 rdf:rest rdf:nil
78 N65029c8deba84ae98ef11eb258910904 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Kidney Failure, Chronic
80 rdf:type schema:DefinedTerm
81 N6915b727761949f184293de9bfa7a23e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Administration, Oral
83 rdf:type schema:DefinedTerm
84 N771d8f9bb5e4426b85117f6bec995d3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Liver Cirrhosis
86 rdf:type schema:DefinedTerm
87 N82c1d00916ab4aa7a817cbad35eccc6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Etodolac
89 rdf:type schema:DefinedTerm
90 N8d9b1bda09b74b2a90472db0ad840ddc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Anti-Inflammatory Agents, Non-Steroidal
92 rdf:type schema:DefinedTerm
93 N902de8bd8a0645929f596b7b6b4f104b rdf:first sg:person.01161574734.50
94 rdf:rest N5d0d924949fb4e6cb04b91f168f08b52
95 Na97c989790044931a729e6cd72a06b16 schema:name Clinical Pharmacology Associates, Miami, FL, USA
96 rdf:type schema:Organization
97 Naf02c88c29df42efa2ed09fa34662bf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Osteoarthritis
99 rdf:type schema:DefinedTerm
100 Nb5646ec17013462695464c00daec659f schema:name dimensions_id
101 schema:value pub.1036724020
102 rdf:type schema:PropertyValue
103 Nc67bff9444ef4bef98afabab843d173c schema:name pubmed_id
104 schema:value 2525981
105 rdf:type schema:PropertyValue
106 Nc8849d82792d4e5dae410f484e107ed5 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 Nd26a4f201d2b4fd7ab04a16c1a711bb1 schema:issueNumber Suppl 1
109 rdf:type schema:PublicationIssue
110 Ne812d7c120304c2697b59db43c658205 schema:name doi
111 schema:value 10.1007/bf02214107
112 rdf:type schema:PropertyValue
113 Ned9232bc640c4284b0606f7fe0b99e83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Indoleacetic Acids
115 rdf:type schema:DefinedTerm
116 Nfa320f899c5c443f937547f2fe255618 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Aged
118 rdf:type schema:DefinedTerm
119 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
120 schema:name Medical and Health Sciences
121 rdf:type schema:DefinedTerm
122 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
123 schema:name Clinical Sciences
124 rdf:type schema:DefinedTerm
125 sg:journal.1093299 schema:issn 0770-3198
126 1434-9949
127 schema:name Clinical Rheumatology
128 rdf:type schema:Periodical
129 sg:person.010430736134.54 schema:affiliation Na97c989790044931a729e6cd72a06b16
130 schema:familyName Lasseter
131 schema:givenName K. C.
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010430736134.54
133 rdf:type schema:Person
134 sg:person.01161574734.50 schema:affiliation https://www.grid.ac/institutes/grid.417143.4
135 schema:familyName Brater
136 schema:givenName D. C.
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161574734.50
138 rdf:type schema:Person
139 sg:pub.10.1038/clpt.1985.244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024842472
140 https://doi.org/10.1038/clpt.1985.244
141 rdf:type schema:CreativeWork
142 sg:pub.10.1038/clpt.1986.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006338285
143 https://doi.org/10.1038/clpt.1986.94
144 rdf:type schema:CreativeWork
145 sg:pub.10.1038/ki.1980.179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033782308
146 https://doi.org/10.1038/ki.1980.179
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1002/bdd.2510050109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021043713
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1002/jps.2600720316 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046369571
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/s0049-0172(86)80005-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050370504
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0140-6736(82)91953-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035303847
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1056/nejm197510022931406 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014354142
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejm198205063061804 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025273847
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1056/nejm198403013100905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024666290
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1056/nejm198503283121305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042677914
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1136/bmj.284.6326.1372 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017933691
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1136/bmj.285.6334.62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034388776
167 rdf:type schema:CreativeWork
168 https://doi.org/10.3109/00498258609043518 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022169678
169 rdf:type schema:CreativeWork
170 https://doi.org/10.3109/03602538108994036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006889200
171 rdf:type schema:CreativeWork
172 https://www.grid.ac/institutes/grid.417143.4 schema:alternateName Wishard Memorial Hospital
173 schema:name Department of Medicine, Division of Clinical Pharmacology, Wishard Memorial Hospital - WOP320, 1001 W. Tenth St., 46202, Indianapolis, IN, USA
174 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...